Incidence and severity of sexual adverse experiences in finasteride and placebo-treated men with benign prostatic hyperplasia

Urology

Volumn 61, Issue 3, 2003, Pages 579-584

  Wessells, Hunter ^b   Roy, Johnny ^b   Bannow, John ^b   Grayhack, John ^b   Matsumoto, Alvin M ^b   Tenover, Lisa ^b   Herlihy, Richard ^b   Fitch, William ^b   Labasky, Richard ^b   Auerbach, Stephen ^b   Parra, Raul ^b   Rajfer, Jacob ^b   Culbertson, Jennifer ^b   Lee, Michael ^b   Bach, Mark A ^b   Waldstreicher, Joanne ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

FINASTERIDE;

ADULT; AGED; ANAMNESIS; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG SAFETY; DRUG SCREENING; EJACULATION DISORDER; ERECTILE DYSFUNCTION; HUMAN; INCIDENCE; LIBIDO DISORDER; MAJOR CLINICAL STUDY; MALE; ORGASM DISORDER; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SEXUAL DYSFUNCTION; TREATMENT OUTCOME;

EID: 0346666783     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(02)02401-9     Document Type: Article

References (24)

1. Feldman H.A., Goldstein I., Hatzichristou D.G., et al. Impotence and its medical and psychosocial correlates results of the Massachusetts Male Aging Study . J Urol. 151:1994;54-61.
2. Macfarlane G.J., Botto H., Sagnier P.-P., et al. The relationship between sexual life and urinary condition in the French community. J Clin Epidemiol. 49:1996;1171-1176.
3. Frankel S.J., Donovan J.L., Peters T.I., et al. Sexual dysfunction in men with lower urinary tract symptoms. J Clin Epidemiol. 51:1998;677-685.
4. Wasson J.H., Reda D.J., Bruskewitz R.C., et al. A comparison of transurethral surgery with watchful waiting for moderate symptoms of benign prostatic hyperplasia. N Engl J Med. 332:1995;75-79.
5. McConnell J.D., Bruskewitz R., Walsh P., et al. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. N Engl J Med. 338:1998;557-563.
6. Gormley G.J., Stoner E., Bruskewitz R.C., et al. The effect of finasteride in men with benign prostatic hyperplasia. N Engl J Med. 327:1992;1185-1191.
7. Marberger M.J. Long-term effects of finasteride in patients with benign prostatic hyperplasia a double-blind, placebo-controlled, multicenter study . Urology. 51:1998;677-686.
8. Andersen J.T., Ekman P., Wolf H., et al. Can finasteride reverse the progress of benign prostatic hyperplasia? A two-year placebo-controlled study. Urology. 46:1995;631-637.
9. Nickel J.C., Fradet Y., Boake R.C., et al. Efficacy and safety of finasteride therapy for benign prostatic hyperplasia results of a 2-year randomized controlled trial (the PROSPECT Study) . Can Med Assoc J. 155:1996;1251-1259.
10. Imperato-McGinley J., Guerrero L., Gautier T., et al. Steroid 5α-reductase deficiency in man an inherited form of male pseudohermaphroditism . Science. 186:1974;1213-1215.
11. Walsh P.C., Madden J.D., Harrod M.J., et al. Familial incomplete male pseudohermaphroditism, type 2 decreased dihydrotestosterone formation in pseudovaginal perineoscrotal hypospadias . N Engl J Med. 291:1974;944-949.
12. Imperato-McGinley J. 5α-reductase-2 deficiency. Curr Ther Endocrinol Metab. 6:1997;384-387.
13. Andersson S., Berman D.M., Jenkins E.P., et al. Deletion of steroid 5α-reductase 2 gene in male pseudohermaphroditism. Nature. 354:1991;159-161.
14. Lowe F.C. Safety assessment of terazosin in the treatment of patients with symptomatic benign prostatic hyperplasia a combined analysis . Urology. 44:1994;46-51.
15. McKiernan J.M., Lowe F.C. Side effects of terazosin in the treatment of symptomatic benign prostatic hyperplasia. South Med J. 90:1997;509-513.
16. Roehrborn C.G., Oesterling J.E., Auerbach S., et al. The Hytrin Community Assessment Trial Study a one-year study of terazosin versus placebo in the treatment of men with symptomatic benign prostatic hyperplasia . Urology. 47:1996;159-168.
17. Kirby R., Roehrborn C., Altwein J.E., et al. Impact of prostate size on response to medical therapy for benign prostatic hyperplasia (BPH) results of the PREDICT trial . (abstract) J Urol. 161:1999;266.
18. Lepor H., Williford W.O., Barry M.J., et al. The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. N Engl J Med. 335:1996;533-539.
19. 1c-adrenoceptor antagonist a randomized, controlled trial in patients with benign prostatic obstruction (symptomatic BPH) . Br J Urol. 76:1995;325-336.
20. 1a-adrenoceptor antagonist. Eur Urol. 29:1996;155-167.
21. Chapple C.R., Baert L., Thind P., et al. Tamsulosin 0.4 mg once daily tolerability in older and younger patients with lower urinary tract symptoms suggestive of benign prostatic obstruction (symptomatic BPH) . Eur Urol. 32:1997;462-470.
22. U.S. product circular for Flomax: Physicians' Desk Reference, 55th ed. Montvale, Medical Economics, 1999, pp 755-758.
23. Bruskewitz R., Fourcade R., Koshiba K., et al. Surgery. Denis L., Griffiths K., Khoury S., et al. 4th International Consultation on Benign Prostatic Hyperplasia (BPH). 1997;523-528 Plymbridge Distributors Ltd, Plymouth.
24. Fowler F.J. Jr, Wennberg J.E., Timothy R.P., et al. Symptom status and quality of life following prostatectomy. J Am Med Assoc. 259:1988;3018-3022.